Background: The aim of this study was to investigate the relationship of body mass index with overall and progression-free survival as well as other prognostic factors of breast cancer in patients with non-metastatic breast cancer. Materials and Methods: We retrospectively reviewed 456 patients diagnosed with breast cancer in the Radiation Oncology department of Kayseri Teaching Hospital between 2005 and 2013. We investigated relationship of body mass index with prognosis and other prognostic factors. Results: The study included 456 patients (447 women and 9 men). Mean age at presentation was 55.6 years. Of the cases, 96.9% underwent modified radical mastectomy and 95.0% received chemotherapy, while 82.4% received radiotherapy and 60.0% were given hormone therapy. Body mass index was >25 mg/kg 2 in 343 cases. Five-and 10-years overall survival rates were 77% and 58% whereas progression-free survival rates were 65% and 49%, respectively. In univariate analyses, factors including stage (p=0.046), tumor diameter (p=0.001), lymph node metastasis (p=0.006) and body mass index (p=0.030) were found to be significantly associated with overall survival, while perinodal involvement was found to be significantly associated with progression-free survival (p=0.
RESEARCH ARTICLE
Relationship of Body Mass Index with Prognosis in Breast Cancer Patients Treated with Adjuvant Radiotherapy and Chemotherapy
Yasemin Benderli CihanThe aim of this study was to investigate whether BMI at diagnosis have prognostic value in breast cancer patients who underwent surgery.
Materials and Methods
Patient group and demographic characteristicsWe retrospectively reviewed operated breast cancer patients who were followed in Radiation Oncology department of Kayseri Teaching Hospital between 2005 and 2013. Patients with missing data and those lost in followup were excluded from analysis. The study was planned in accordance to local ethics regulations and Helsinki Declaration. We reviewed age, gender, menopausal status, family history of breast cancer, height, weight, BMI, tumor localization, tumor stage, surgery type, histopathological findings, data regarding chemotherapy and radiotherapy, and survival times. In the histopathological diagnosis, tumor type, tumor localization, tumor diameter, lymphatic metastasis, number of lymph nodes excised, number of lymph nodes with metastatic infiltration, level of estrogen and progesterone receptors, cerb-B2 status, grade, and Yasemin Benderli Cihan